Logo image of ALESE.PA

ENTECH SACA (ALESE.PA) Stock Fundamental Analysis

Europe - Euronext Paris - EPA:ALESE - FR0014004362 - Common Stock

7.98 EUR
0 (0%)
Last: 12/22/2025, 7:00:00 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to ALESE. ALESE was compared to 41 industry peers in the Construction & Engineering industry. ALESE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ALESE is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

ALESE had negative earnings in the past year.
ALESE had a positive operating cash flow in the past year.
In the past 5 years ALESE reported 4 times negative net income.
ALESE had a negative operating cash flow in each of the past 5 years.
ALESE.PA Yearly Net Income VS EBIT VS OCF VS FCFALESE.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 -2M -4M -6M -8M -10M

1.2 Ratios

With a Return On Assets value of -3.90%, ALESE is not doing good in the industry: 92.68% of the companies in the same industry are doing better.
The Return On Equity of ALESE (-11.24%) is worse than 87.80% of its industry peers.
Industry RankSector Rank
ROA -3.9%
ROE -11.24%
ROIC N/A
ROA(3y)-2.34%
ROA(5y)-0.87%
ROE(3y)-4.85%
ROE(5y)-2.97%
ROIC(3y)N/A
ROIC(5y)N/A
ALESE.PA Yearly ROA, ROE, ROICALESE.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 10 -10

1.3 Margins

ALESE has a Gross Margin (42.82%) which is comparable to the rest of the industry.
In the last couple of years the Gross Margin of ALESE has declined.
ALESE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 42.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.07%
GM growth 5YN/A
ALESE.PA Yearly Profit, Operating, Gross MarginsALESE.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 20 40 60

6

2. Health

2.1 Basic Checks

ALESE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ALESE remains at a similar level compared to 1 year ago.
ALESE has a worse debt/assets ratio than last year.
ALESE.PA Yearly Shares OutstandingALESE.PA Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 5M 10M
ALESE.PA Yearly Total Debt VS Total AssetsALESE.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

An Altman-Z score of 2.28 indicates that ALESE is not a great score, but indicates only limited risk for bankruptcy at the moment.
ALESE has a Altman-Z score of 2.28. This is in the better half of the industry: ALESE outperforms 65.85% of its industry peers.
ALESE has a debt to FCF ratio of 1.82. This is a very positive value and a sign of high solvency as it would only need 1.82 years to pay back of all of its debts.
ALESE has a better Debt to FCF ratio (1.82) than 78.05% of its industry peers.
A Debt/Equity ratio of 0.27 indicates that ALESE is not too dependend on debt financing.
The Debt to Equity ratio of ALESE (0.27) is better than 75.61% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF 1.82
Altman-Z 2.28
ROIC/WACCN/A
WACC7.68%
ALESE.PA Yearly LT Debt VS Equity VS FCFALESE.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

ALESE has a Current Ratio of 1.57. This is a normal value and indicates that ALESE is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of ALESE (1.57) is better than 87.80% of its industry peers.
ALESE has a Quick Ratio of 1.51. This is a normal value and indicates that ALESE is financially healthy and should not expect problems in meeting its short term obligations.
ALESE has a better Quick ratio (1.51) than 90.24% of its industry peers.
Industry RankSector Rank
Current Ratio 1.57
Quick Ratio 1.51
ALESE.PA Yearly Current Assets VS Current LiabilitesALESE.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

7

3. Growth

3.1 Past

ALESE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -294.30%.
The Revenue has grown by 32.45% in the past year. This is a very strong growth!
Measured over the past years, ALESE shows a very strong growth in Revenue. The Revenue has been growing by 68.95% on average per year.
EPS 1Y (TTM)-294.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.1%
Revenue 1Y (TTM)32.45%
Revenue growth 3Y68.95%
Revenue growth 5YN/A
Sales Q2Q%56.95%

3.2 Future

The Earnings Per Share is expected to grow by 110.19% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 38.85% on average over the next years. This is a very strong growth
EPS Next Y128.57%
EPS Next 2Y117.12%
EPS Next 3Y110.19%
EPS Next 5YN/A
Revenue Next Year38.3%
Revenue Next 2Y50.27%
Revenue Next 3Y51.15%
Revenue Next 5Y38.85%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ALESE.PA Yearly Revenue VS EstimatesALESE.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
ALESE.PA Yearly EPS VS EstimatesALESE.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 0.2 0.4 0.6

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALESE. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 27.18, the valuation of ALESE can be described as expensive.
75.61% of the companies in the same industry are cheaper than ALESE, based on the Price/Forward Earnings ratio.
ALESE's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 24.01.
Industry RankSector Rank
PE N/A
Fwd PE 27.18
ALESE.PA Price Earnings VS Forward Price EarningsALESE.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

ALESE's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. ALESE is cheaper than 73.17% of the companies in the same industry.
Industry RankSector Rank
P/FCF 8.89
EV/EBITDA N/A
ALESE.PA Per share dataALESE.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

ALESE's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ALESE's earnings are expected to grow with 110.19% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y117.12%
EPS Next 3Y110.19%

0

5. Dividend

5.1 Amount

ALESE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

ENTECH SACA

EPA:ALESE (12/22/2025, 7:00:00 PM)

7.98

0 (0%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryConstruction & Engineering
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners11.71%
Inst Owner ChangeN/A
Ins Owners63.76%
Ins Owner ChangeN/A
Market Cap117.15M
Revenue(TTM)45.47M
Net Income(TTM)-2.92M
Analysts86
Price Target11.63 (45.74%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)500%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 27.18
P/S 2.58
P/FCF 8.89
P/OCF 8.26
P/B 4.51
P/tB 5.91
EV/EBITDA N/A
EPS(TTM)-0.2
EYN/A
EPS(NY)0.29
Fwd EY3.68%
FCF(TTM)0.9
FCFY11.25%
OCF(TTM)0.97
OCFY12.1%
SpS3.1
BVpS1.77
TBVpS1.35
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -3.9%
ROE -11.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 42.82%
FCFM 28.98%
ROA(3y)-2.34%
ROA(5y)-0.87%
ROE(3y)-4.85%
ROE(5y)-2.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.07%
GM growth 5YN/A
F-Score3
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF 1.82
Debt/EBITDA N/A
Cap/Depr -3341.67%
Cap/Sales 2.2%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.57
Quick Ratio 1.51
Altman-Z 2.28
F-Score3
WACC7.68%
ROIC/WACCN/A
Cap/Depr(3y)285.26%
Cap/Depr(5y)212.15%
Cap/Sales(3y)7.1%
Cap/Sales(5y)9.44%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-294.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.1%
EPS Next Y128.57%
EPS Next 2Y117.12%
EPS Next 3Y110.19%
EPS Next 5YN/A
Revenue 1Y (TTM)32.45%
Revenue growth 3Y68.95%
Revenue growth 5YN/A
Sales Q2Q%56.95%
Revenue Next Year38.3%
Revenue Next 2Y50.27%
Revenue Next 3Y51.15%
Revenue Next 5Y38.85%
EBIT growth 1Y-189.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year282.86%
EBIT Next 3Y157.7%
EBIT Next 5Y101.83%
FCF growth 1Y230.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y258.95%
OCF growth 3YN/A
OCF growth 5YN/A

ENTECH SACA / ALESE.PA FAQ

What is the fundamental rating for ALESE stock?

ChartMill assigns a fundamental rating of 4 / 10 to ALESE.PA.


Can you provide the valuation status for ENTECH SACA?

ChartMill assigns a valuation rating of 3 / 10 to ENTECH SACA (ALESE.PA). This can be considered as Overvalued.


What is the profitability of ALESE stock?

ENTECH SACA (ALESE.PA) has a profitability rating of 1 / 10.


Can you provide the financial health for ALESE stock?

The financial health rating of ENTECH SACA (ALESE.PA) is 6 / 10.